fashion -WSS

fashion

author：explore 2025-09-07 00:17:11 - browse：595

TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drugmakers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Over four hours, the debate spanned most of the substantive issues that pharmaceutical companies and their allies have raised across the country, both in constitutional challenges to the law and in challenges to how Medicare officials have interpreted the law so far. That means the court’s decision in these cases could produce a first substantive test for several of the arguments that haven’t been addressed by courts in other states, where companies like Boehringer Ingelheim, AstraZeneca, and Merck are also suing, separately, over the same law.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： After gene therapy, two congenitally deaf children hear for the first time

WSS

Researchers on aging grapple with how to calculate biological age

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Artificial intelligence use in health care faces greater scrutiny in 2024

Abbott's new heart device gets FDA advisory panel nod

Artificial intelligence use in health care faces greater scrutiny in 2024

What nurses really want: sufficient staffing for patient care

Wikipedia

fashion

knowledge

Peter Hotez and the public health issue of online harassment

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

DIEP, the 'gold standard' of breast reconstruction, is under threat

Long Covid research funding gets a major boost from NIH

How to save PrEP access — and even expand it

Why Eli Lilly’s earnings didn’t quite live up to the hype

Medicare details structure of new drug price negotiation program

Use wet bulb globe temperature, not heat index, to protect workers

Dobbs anniversary: the lost opportunity of abortion as health care

Why Eli Lilly’s earnings didn’t quite live up to the hype

hotspot

Elevance, private equity launch primary care company

Why Eli Lilly’s earnings didn’t quite live up to the hype

Tome Biosciences co

Sanofi strikes deal with Novavax, boosting the vaccine maker

CDC wastewater surveillance dashboard to track bird flu hotspots

Latigo launches with $135 million for Vertex

explore

hotspot

knowledge

hotspot